Below is a bibliography of Travere’s peer-reviewed manuscripts in reverse chronological order. For more information, including poster presentations, and upcoming medical congress activity, please visit Medical Affairs.
2025
Szklarzewicz J, Floege U, Gallego D, et al. The humanistic burden of focal segmental glomerulosclerosis on patients and care-partners in the United States. Qual Life Res. 2025. https://doi.org/10.1007/s11136-025-03951-w
Tuttle KR, Kornowske LM, Jones CR, et al. Population-Level Risk Factors for Kidney Outcomes in IgA Nephropathy: The CURE-CKD Registry. Kidney Med. 2025;4(7):100981 https://doi.org/10.1016/j.xkme.2025.100981
Trachtman H, Komers R, Inrig JK. Sparsentan clinical trials in glomerular diseases: defining endpoints and a path forward in light of the parasol initiative. Future Rare Dis. 2025;5(1). https://doi.org/10.1080/23995270.2025.2461966.
Jain M, Shah M, Thakker KM, et al. Impact of classical homocystinuria on health care resource utilization and costs in the United States: A retrospective cohort study. Mol Genet Metab Rep. 2025 Jan 25:42:101192. https://doi.org/10.1016/j.ymgmr.2025.101192.
Bedard PW, Pretto F, Patel S, et al. The dual endothelin A and angiotensin II type 1 receptor antagonist sparsentan exhibits a safe nonclinical male fertility toxicity profile. Regul Toxicol Pharmacol. 2025;156:105770. https://doi.org/10.1016/j.yrtph.2024.105770.
Pitcher D, Barratt J, Hendry B, et al. A plain language summary of a study of long-term outcomes in patients with IgA nephropathy from the UK National Registry of Rare Kidney Diseases (RaDaR). Future Rare Dis. 2024;5(1). https://doi.org/10.1080/23995270.2024.2439237.
2024
Mariani LH, Trachtman H, Thompson A, et al. Proteinuria as an Endpoint in Clinical Trials of Focal Segmental Glomerulosclerosis. Am J Kidney Dis. 2024:S0272-6386(24)01038-2. https://doi.org/10.1053/j.ajkd.2024.08.011.
Jain M, Shah M, Thakker KM, et al. Estimating prevalence of classical homocystinuria in the United States using Optum’s de-identified market clarity data. Molecular Genetics and Metabolism Reports. 2024 Jun. https://doi.org/10.1016/j.ymgmr.2024.101101.
Kohan DE, Bedard PW, Jenkinson C, Hendry B, Komers R. Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease. Clin Sci (Lond) 5 June 2024; 138 (11): 645–662. doi: https://doi.org/10.1042/CS20240249.
Szklarzewicz J, Floege U, Gallego D, et al. The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States. Qual Life Res. 2024. Epub ahead of print. https://doi.org/10.1007/s11136-024-03813-x
Campbell KN, Gesualdo L, Murphy E, et al. Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open Label Extension: Long-Term Efficacy and Safety. Kidney Medicine 2024 Article In Press. https://doi.org/10.1016/j.xkme.2024.100833.
Velez JCQ, Thakker KM, Bensink ME, et al. Cardiovascular, Kidney Failure, and All-Cause Mortality Events in Patients with Focal Segmental Glomerulosclerosis in a US Real-World Database. Kidney360. 2024;5(8):1145-1153. https://doi.org/10.34067/kid.0000000000000469
Reily C, Moldoveanu Z, Pramparo T, et al. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy. Am J Physiol Renal Physiol. 2024 Mar 21. https://doi.org/10.1152/ajprenal.00253.2023.
Gyarmati G, Shroff UN, Izuhara AK, et al. Sparsentan Improves Glomerular Hemodynamics, Cell Functions and Tissue Repair in a Mouse Model of FSGS. JCI Insight. 2024;e177775. https://doi.org/10.1172/jci.insight.177775
Zhou Z-Y, Bensink ME, Hazra NC. Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis. Pharmacoecon Open. 2024; Online ahead of print. https://doi.org/10.1007/s41669-024-00527-1
Heo YA, Kang C. Sparsentan in Immunoglobulin A Nephropathy: a Profile of its Use. Drugs Ther Perspect. 2024;40:101-108.
https://doi.org/10.1007/s40267-024-01058-9
Rovin B, Hendry B, Cheung CK. Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile. EMJ. 2024;9(1):13-21. https://doi.org/10.33590/emj/11000020
Trachtman H, Komers R, Inrig J. Sparsentan: the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy. Expert Rev Clin Immunol. 2024;20(6):571-576. https://doi.org/10.1080/1744666x.2024.2319132
Nagasawa H, Ueda S, Suzuki H, et al. Sparsentan is Superior to Losartan in the gddY Mouse Model of IgA Nephropathy. Nephrol Dial Transplant. 2024; gfae021. https://doi.org/10.1093/ndt/gfae021
Lerma EV, Thakker KM, Bensink ME, et al. Kidney Failure Events, Cardiovascular Disease Events and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database. Kidney360. 2024; Epub ahead of print. https://doi.org/10.34067/kid.0000000000000379
Trachtman H, Radhakrishnan J, Rheault MN, et al. Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study. Kidney Int Rep. 2024; In Press Journal Pre-Proof. https://doi.org/10.1016/j.ekir.2024.01.032
Bensink ME, Goldschmidt D, Zhou Z-Yi, et al. Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden. Kidney Med. 2024;6(2):100760. https://doi.org/10.1016/j.xkme.2023.100760
Patel NK, Chen K-F, Chen S-C, et al. Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential. CPT Pharmacometrics Syst Pharmacol. 2024;13(2):317-329. https://doi.org/10.1002/psp4.13086
2023
Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 2023; published online Nov 3. doi: 10.1016/S0140-6736(23)02302-4.
Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. Epub ahead of print. N Engl J Med. 2023 Nov 3. doi: 10.1056/NEJMoa2308550.
Trachtman H, Diva U, Murphy E, et al. Implications of complete proteinuria remission at any time in focal segmental glomerulosclerosis: sparsentan DUET trial. Kidney Int Rep. 2023;Aug 3 [Epub ahead of print]. https://doi.org/10.1016/j.ekir.2023.07.022
Caster DJ, Abner CW, Walker PD, et al. Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep. 2023;Jun 27 [Epub ahead of print]. https://doi.org/10.1016/j.ekir.2023.06.016
Lerma EV, Bensink ME, Thakker KM, et al. Impact of proteinuria and kidney function decline on health care costs and resource utilization in adults with IgA nephropathy in the United States: a retrospective analysis. Kidney Med. 2023;5(9):100693. https://doi.org/10.1016/j.xkme.2023.100693
Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. 2023;401(10388):1584-1594. https://doi.org/10.1016/S0140-6736(23)00569-X
Cosgrove D, Gratton MA, Madison J, et al. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J Pathol. 2023;260(3):353-364. https://doi.org/10.1002/path.6087
Wada R, Kleijn HJ, Zhang L, et al. Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis. CPT Pharmacometrics Syst Pharmacol. 2023;12(8):1080-1092. https://doi.org/10.1002/psp4.12996
Chen S-C, Cai D, Winnett C, et al. Effect of multiple doses of sparsentan on the single-dose pharmacokinetics of dapagliflozin: an open-label drug–drug interaction study in healthy adults. Clin Pharmacol Drug Dev. 2023;12(5):535-541. https://doi.org/10.1002/cpdd.1231
Jhaveri KD, Bensink ME, Bunke M, et al. Humanistic and economic burden of IgA nephropathy: systematic literature reviews and narrative synthesis. Pharmacoecon Open. 2023;Apr 27 [Epub ahead of print]. https://doi.org/10.1007/s41669-023-00415-0
Stamellou E, Nadal J, Hendry B, et al. Long-term outcomes of adults with FSGS in the German chronic kidney disease cohort. Clin Kidney J. 2024;17(7):sfae131. https://doi.org/10.1093/ckj/sfae131
Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. https://doi.org/10.2215/CJN.0000000000000135
Barratt J, Rovin B, Wong MG, et al. IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. Kidney Int Rep. 2023;8(5):1043-1056. https://doi.org/10.1016/j.ekir.2023.02.1086
2022
Mikel C, Goldfarb DS, Ponte A, Steigelman K, Latyshev S, Goldfarb D. Accurate 24-h urine cystine quantification for patients on cystine-binding thiol drugs. Urolithiasis. 2022 Dec;50(6):721-727. doi: 10.1007/s00240-022-01364-9. Epub 2022 Oct 6.
Caster DJ, Magalhaes B, Pennese N, et al. Efficacy and safety of immunosuppressive therapy in primary focal segmental glomerulosclerosis: a systematic review and meta-analysis. Kidney Med. 2022;4:100501. https://doi.org/10.1016/j.xkme.2022.100501
Floege J, Barratt J, Coppo R, et al. International physicians Delphi survey: managing patients with IgA nephropathy. Kidney Int Rep. 2022;7(9):2076-2080. https://doi.org/10.1016/j.ekir.2022.05.022
Campbell KN, Pennese N, Zaffalon A, et al. Efficacy and safety of ACE inhibitor and angiotensin receptor blocker therapies in primary focal segmental glomerulosclerosis treatment: a systematic review and meta-analysis. Kidney Med. 2022;4(5):100457. https://doi.org/10.1016/j.xkme.2022.100457
2020
Komers R, Diva U, Inrig JK, et al. Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep. 2020;5(4):494-502. https://doi.org/10.1016/j.ekir.2019.12.017
Trachtman H, Hogan JJ, Tesar V, et al. dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, treatment of focal segmental glomerulosclerosis, treatment of IgA nephropathy. Drugs Future. 2020;45(2):79-98 https://doi.org/10.1358/dof.2020.45.2.3058863
2019
Barratt J, Rovin B, Diva U, et al. Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial). Kidney Int Rep. 2019;4(11):1633-1637. https://doi.org/10.1016/j.ekir.2019.08.007
Modersitzki F, Goldfarb DS, Goldstein RL, Sur RL, Penniston KL. Assessment of health-related quality of life in patients with cystinuria on tiopronin therapy. Urolithiasis. 2020 Aug;48(4):313-320. doi: 10.1007/s00240-019-01174-6. Epub 2019 Dec 13.
2018
Trachtman H, Nelson P, Adler S, et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745-2754. https://doi.org/10.1681/ASN.2018010091
2017
Komers R, Gipson DS, Nelson P, et al. Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET). Kidney Int Rep. 2017;2(4):654-664. https://doi.org/10.1016/j.ekir.2017.02.019
2016
Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R877-R884. https://doi.org/10.1152/ajpregu.00425.2015
RET246 07/2023